You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

376 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Scientist, Surveillance Research, Acute and Hospital-Based Care, Ontario Health todd.norwood@ontariohealth.ca  
Chercheur, Recherche en matière de surveillance, Soins aigus et hospitaliers, Santé Ontario todd.norwood@ontariohealth.ca  
Drug
Other Name(s): Camptosar®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2023
Drug
Other Name(s): Imjudo®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Drug
Other Name(s): Herceptin® , Kanjinti™; Ogivri™; Trazimera™; Herzuma®; Ontruzant®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2024
Drug
Other Name(s): Tecvayli®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2025
Document
New
Jan 2025
Guidelines and Advice
Status: Current
ID: MOTAC-7
Updated
Jan 2025
Drug
Other Name(s): Sarclisa®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2024
Drug
Other Name(s): Trecondyv®
Quick Link(s):
Drug Monograph
Jan 2025
Drug
Other Name(s): Tukysa™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025

Pages